Results 151 to 160 of about 4,254,417 (298)
Aggressive prostate cancer is associated with pericyte dysfunction
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero +11 more
wiley +1 more source
FOXO1 Inhibition and FADD Knockdown Have Opposing Effects on Anticancer Drug-Induced Cytotoxicity and p21 Expression in Osteosarcoma Cells. [PDF]
Walker D +5 more
europepmc +1 more source
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen, D. Flies
semanticscholar +1 more source
Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis [PDF]
Melanie C. Dispenza +5 more
openalex +1 more source
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard +12 more
wiley +1 more source
Antimicrobial susceptibility testing of <i>Aggregatibacter Actinomycetemcomitans</i> can be performed using the EUCAST medium for anaerobic bacteria. [PDF]
Jensen AB +3 more
europepmc +1 more source
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang +8 more
wiley +1 more source
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Citation Delmore +25 more
semanticscholar +1 more source
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard +5 more
wiley +1 more source

